Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O76061
UPID:
STC2_HUMAN
Alternative names:
Stanniocalcin-related protein
Alternative UPACC:
O76061
Background:
Stanniocalcin-2, also known as Stanniocalcin-related protein, plays a crucial role in calcium and phosphate homeostasis, exhibiting an anti-hypocalcemic action. This protein's unique function in regulating mineral balance underscores its importance in physiological processes.
Therapeutic significance:
Understanding the role of Stanniocalcin-2 could open doors to potential therapeutic strategies. Its pivotal role in mineral regulation presents an opportunity for developing treatments targeting metabolic disorders.